“…HSP90 makes the mutated oncoproteins able to avoid misfolding and degradation and permits the malignant transformation (Barrott & Haystead, 2013; Wu et al, 2017). HSP90 promotes the growth and inhibits apoptosis in multiple types of cancers, such as bladder carcinoma (Lebret et al, 2003), medulloblastoma (Alexiou et al, 2013), renal (Zhu, Zhu, Qi, & Qiu, 2015), lung (Esfahani & Cohen, 2016), colorectal (Moser et al, 2007), and acute leukemia (Tian et al, 2014) as well as HCC (Dong, Xue, et al, 2018; C. Wang, Zhang, et al, 2016). More recently, it was shown that the HSP90 is a potential biomarker of HCC, and the diagnostic value of its expression for HCC detection was reported (Wei et al, 2020).…”